AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29296707
Drug: Posttransplant cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posttransplant cyclophosphamide (PT-Cy) at 0 mg/kg in cohort 1
Trial: 29296707
Drug: Posttransplant cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posttransplant cyclophosphamide (PT-Cy) at 50 mg/kg in cohort 2
Trial: 29296707
Drug: Posttransplant cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posttransplant cyclophosphamide (PT-Cy) at 100 mg/kg in cohort 3
Trial: 29296758
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin (InO) 1.2 mg/m²
Trial: 29296758
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin (InO) 1.6 mg/m²
Trial: 29296758
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin (InO) 1.8 mg/m²
Trial: 29296838
Drug: Sonidegib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonidegib (200 mg/day, 400 mg/day, 600 mg/day) for up to 12 cycles of 28 days each
Trial: 29296873
Drug: Bortezomib maintenance
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib maintenance therapy after tandem autologous/allogeneic hematopoietic cell transplantation
Trial: 29296873
Drug: High-dose conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose conditioning regimen with melphalan 200 mg/m2 for autologous hematopoietic cell transplantation
Trial: 29298867
Drug: dezamizumab (fully
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dezamizumab (fully humanized monoclonal IgG1 anti-SAP antibody)
Trial: 29298867
Drug: miridesap (small-molecule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: miridesap (small-molecule drug)
Trial: 29299030
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of warfarin in low-risk patients with sustained sinus rhythm
Trial: 29300435
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of drugs used or causative drug use
Trial: 29301580
Drug: PEGASYS® (pegylated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGASYS® (pegylated interferon alfa-2a from Roche Pharmaceutical)
Trial: 29302336
Drug: Acellular bioscaffolds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular bioscaffolds composed of mammalian extracellular matrix (ECM) implanted with aggressive and early physical therapy
Trial: 29302336
Drug: Acellular bioscaffolds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular bioscaffolds with physical therapy
Trial: 29304833
Drug: Selinexor (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor (80 mg/day) in combination with high-dose cytarabine and mitoxantrone (HiDAC/Mito)
Trial: 29305501
Drug: Lactobacillus supplementation
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus supplementation or intervention, specific dosage and duration not mentioned
Trial: 29305552
Drug: Venetoclax (initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (initiated at 20 mg daily, ramped up to 400 mg daily)
Trial: 29306203
Drug: Pulsed low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pulsed low-dose rate radiotherapy (PLDR) - 10 fractions of 2 Gy/day, with an interval of 3 minutes, for 5 days per week; dose rate 6.67 cGy/min
Trial: 29306203
Drug: Pulsed low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pulsed low-dose rate radiotherapy (PLDR)
Trial: 29306459
Drug: Serum uric
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum uric acid (sUA) levels (using diuretics)
Trial: 29306459
Drug: Serum uric
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum uric acid (sUA) levels (not using diuretics)
Trial: 29306506
Drug: On-time dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-time dosing (control group)
Trial: 29306506
Drug: Substantially late
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substantially late dose 3 (group 2)
Trial: 29306506
Drug: Substantially late
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substantially late dose 2, on-time dose 3 (group 3)
Trial: 29306506
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses substantially late (group 4)
Trial: 29306506
Drug: On-time dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-time dose 2
Trial: 29306506
Drug: Substantially late
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substantially late dose 2
Trial: 29306769
Drug: Ipilimumab at
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab at a dose of 10 mg/kg in week 1, 4, 7, 10 followed by 3-month maintenance treatment for a maximum of 48 weeks
Trial: 29309319
Drug: Low-risk group
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-risk group (50 mg/kg TXA bolus)
Trial: 29309319
Drug: High-risk group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk group (loading dose 30 mg/kg, infusion 16 mg/kg/h with 2 mg/kg in pump prime)
Trial: 29310641
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment (specifics not provided)
Trial: 29310641
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of life questionnaires (EuroQoL EQ-5D-5 L, EORTC QLQ-C30, QLQ-BR23, Hospital Anxiety and Depression Scale)
Trial: 29310710
Drug: Active LLLT
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active LLLT (low-level laser therapy)
Trial: 29310869
Drug: Intravenous vascular
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vascular access
Trial: 29311069
Drug: Meropenem-Vaborbactam, single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem-Vaborbactam, single-dose administration, specific dosage not mentioned.
Trial: 29311086
Drug: Artemether-Lumefantrine; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-Lumefantrine; specific dosage and duration not provided
Trial: 29311094
Drug: Telavancin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telavancin at fixed doses
Trial: 29312948
Drug: Controlled diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled diet of 1.2 g/kg protein for 2 days
Trial: 29313282
Drug: Ertugliflozin 5
RxNorm normalized name: ertugliflozin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin 5 mg once daily and Sitagliptin 100 mg once daily (E5/S100)
Trial: 29313282
Drug: Ertugliflozin 15
RxNorm normalized name: ertugliflozin 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin 15 mg once daily and Sitagliptin 100 mg once daily (E15/S100)
Trial: 29315015
Drug: Forced expression
RxNorm normalized name: benzalkonium chloride Topical Solution [Clean Force]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forced expression of a dominant-negative TGF-β receptor type 2 (DNRII)
Trial: 29317417
Drug: New group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New group-based treatment programme combining physical exercise and dietary therapy
Trial: 29318759
Drug: Dietary sodium
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary sodium intake of 500 mg/d higher
Trial: 29318795
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion rates at T1, T2, and T3
Trial: 29319721
Drug: Vasopressin infusion
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin infusion at 0.04 U/min for one hour
Trial: 29319721
Drug: Baseline noradrenaline
RxNorm normalized name: noradrenaline hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline noradrenaline dose
Trial: 29319721
Drug: Noradrenaline dose
RxNorm normalized name: noradrenaline hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline dose higher than 0.38 mcg/kg/min
Trial: 29319932
Drug: Tedizolid phosphate
RxNorm normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tedizolid phosphate 200 mg (single oral dose)
Trial: 29321026
Drug: Combination intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination intervention administered by trained lay health workers including appointment reminders via text and phone calls, follow-up and tracking for missed clinic visits, PMTCT health education at home visits and during clinic visits, and retention and adherence support and counseling.
Trial: 29321026
Drug: Combination intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination intervention administered by trained lay health workers.
Trial: 29321041
Drug: Prophylactic proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic proton pump inhibitor
Trial: 29321063
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment with autologous adipose-derived stromal vascular fraction (ADSVF) and microfat; 14 ml of microfat and approximately 20 million viable ADSVF cells injected.
Trial: 29321075
Drug: H1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 vaccine alone (group 1)
Trial: 29321075
Drug: H1/IC31® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1/IC31® vaccine (groups 2, 3, and 4)
Trial: 29321155
Drug: Plasminogen replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasminogen replacement therapy
Trial: 29322091
Drug: Toca 511
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toca 511 and Toca FC (extended-release 5-FC)
Trial: 29324745
Drug: Digital intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital intervention for ADHD, 28 days of at-home treatment
Trial: 29325133
Drug: Metformin (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (daily for 24 months)
Trial: 29325161
Drug: Japanese Encephalitis
RxNorm normalized name: Japanese Encephalitis IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) booster
Trial: 29325173
Drug: Pneumococcal conjugate
RxNorm normalized name: pneumococcal conjugate PCV 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal conjugate vaccine (PCV13) or pneumococcal polysaccharide vaccine (PPV23)
Trial: 29325173
Drug: Pneumococcal polysaccharide
RxNorm normalized name: pneumococcal polysaccharides (23)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal polysaccharide vaccine (PPV23)
Trial: 29325238
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not prescribed antidepressants)
Trial: 29325521
Drug: Single-agent gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent gemcitabine (1000 mg/m²)
Trial: 29325595
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of 10% dextrose 5 mL/kg followed by a dextrose infusion in addition to standard care
Trial: 29326029
Drug: Trastuzumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (8 mg/kg loading dose followed by 6 mg/kg), Pertuzumab (840 mg loading dose followed by 420 mg), Palbociclib (125 mg once a day for 21 days), Fulvestrant (500 mg every 4 weeks)
Trial: 29326917
Drug: Daily PrEP
RxNorm normalized name: Zinc Oxide 238 mg in 1 mL / Titanium Dioxide 41 mg in 1 mL TOPICAL LOTION [bareMinerals Prep Step Mineral Shield Broad Spectrum SPF 50 Daily Prep]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily PrEP (one pill taken every day)
Trial: 29326917
Drug: Event-driven PrEP
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Event-driven PrEP (pills taken only around specific risk events)
Trial: 29326917
Drug: Periodic PrEP
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodic PrEP (daily dosing during periods of increased risk)
Trial: 29327075
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg orally twice a day, oxaliplatin 85 mg/m2
Trial: 29327182
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg ferrous fumarate in tablet form (195 mg of elemental iron)
Trial: 29327182
Drug: 1390 mg
RxNorm normalized name: Mg
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1390 mg ferrous gluconate as a solution (160 mg of elemental iron)
Trial: 29330782
Drug: Vilaprisan 5
RxNorm normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan 5 mg single oral administration
Trial: 29330782
Drug: Vilaprisan administered
RxNorm normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan administered with itraconazole
Trial: 29331969
Drug: Antithrombotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic treatment initiated at diagnosis
Trial: 29331969
Drug: Guideline-recommended therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-recommended therapy
Trial: 29333165
Drug: Intramyocardial injections
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramyocardial injections of autologous VEGF-A
Trial: 29334491
Drug: AZL-M/CTD 20/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZL-M/CTD 20/12.5 mg once daily titrated to 40/25 mg if needed
Trial: 29334491
Drug: AZL-M/CTD 40/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZL-M/CTD 40/12.5 mg once daily titrated to 80/25 mg if needed
Trial: 29334491
Drug: OLM/HCTZ 20/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLM/HCTZ 20/12.5 mg once daily titrated to 40/25 mg if needed
Trial: 29334491
Drug: AZL-M/CTD lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZL-M/CTD lower dose
Trial: 29334491
Drug: AZL-M/CTD higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZL-M/CTD higher dose
Trial: 29335333
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (initially pursued)
Trial: 29335333
Drug: No active
RxNorm normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active treatment (discontinued after admission)
Trial: 29335831
Drug: Extracorporeal membrane
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal membrane oxygenation treatment
Trial: 29338080
Drug: Cisplatin, gemcitabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin, gemcitabine, and veliparib (80 mg twice daily on days 1 to 12)
Trial: 29338080
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and gemcitabine (600 mg/m2 and 25 mg/m2 respectively)
Trial: 29339269
Drug: Intravenous busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m2)
Trial: 29339394
Drug: Finafloxacin; administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finafloxacin; administered orally
Trial: 29339403
Drug: Azacitidine combined
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine combined with chemotherapy
Trial: 29339691
Drug: Cross-sectional survey
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross-sectional survey of public perception and knowledge of cholesterol treatment
Trial: 29341967
Drug: Inhaled Nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Nitric Oxide (NO) at an initial dose of 10 (10, 15) ppm for adults, 20 (18, 20) ppm for children, and 17 (11, 20) ppm for neonates, administered for a median duration of 3.9 (1.9, 6.1) days for adults, 3.8 (1.8, 6.8) days for children, and 3.1 (1.0, 5.7) days for neonates.
Trial: 29342267
Drug: 0.50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 mg/kg of SLD-PQ
Trial: 29342267
Drug: 0.40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.40 mg/kg of SLD-PQ
Trial: 29344432
Drug: WT1 peptide
RxNorm normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WT1 peptide vaccine with Montanide as an adjuvant
Trial: 29344726
Drug: Elbasvir 50
RxNorm normalized name: elbasvir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elbasvir 50 mg plus grazoprevir 100 mg once daily for 12 weeks
Trial: 29345044
Drug: TAK-063 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-063 at 0.3 mg/kg
Trial: 29346377
Drug: Community-wide mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-wide mass drug administration (MDA) delivered door-to-door, twice annually for three years.
Trial: 29346388
Drug: 18 mg
RxNorm normalized name: niacin 18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg ivermectin tablet
Trial: 29346388
Drug: 36 mg
RxNorm normalized name: pyrantel 136 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 mg ivermectin tablet
Trial: 29346388
Drug: Standard weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard weight-based regimen (150–200 μg/kg)
Trial: 29346478
Drug: Enasidenib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enasidenib (50 to 650 mg/d during dose-escalation; 100 mg/d during phase 1 expansion and phase 2)
Trial: 29346519
Drug: Cetuximab 400
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab 400 mg/m2 loading dose in week 1 followed by 250 mg/m2 weekly and cisplatin 30 mg/m2 concurrent with 6 weeks of intensity-modulated radiotherapy (60-66 Gy in 30 daily fractions)
Trial: 29346834
Drug: Ravidasvir (RDV)
RxNorm normalized name: Ravidasvir
DrugBank: Ravidasvir (DB15652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ravidasvir (RDV) 200 mg once daily plus ritonavir-boosted danoprevir (DNVr) 100 mg/100 mg twice daily and oral ribavirin (RBV) 1000/1200 mg/day for 12 weeks
Trial: 29346833
Drug: Ficlatuzumab in
RxNorm normalized name: Ficlatuzumab
DrugBank: Ficlatuzumab (DB11680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ficlatuzumab in combination with Gefitinib
Trial: 29347915
Drug: Self-reported current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported current insulin use
Trial: 29347987
Drug: Clinical and
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical and biological parameters at ICU discharge including N-terminal pro-B type natriuretic peptide, high-sensitive troponin I, bioactive-adrenomedullin, and soluble-ST2.
Trial: 29347993
Drug: Avelumab 10
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 10 mg/kg by 1-h intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal.
Trial: 29348128
Drug: Pevonedistat (PEV)
RxNorm normalized name: econazole nitrate Topical Powder [Pevaryl]
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pevonedistat (PEV) 20 or 30 mg/m² combined with azacitidine (AZA)
Trial: 29349065
Drug: Omega-3 acids
RxNorm normalized name: Fish oil containing omega-3 acids
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 acids supplementation (2 g/day)
Trial: 29349545
Drug: Bare-metal stents
RxNorm normalized name: menthone 1,2-glycerol ketal, (-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bare-metal stents (BMS) with clopidogrel 75 mg for 4 weeks
Trial: 29349545
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents (DES) without HTPR with clopidogrel for 6 months
Trial: 29349545
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents (DES) with HTPR with clopidogrel for 6 months